Managing Infection Risks in BCMA Bispecific Antibody Therapy: Ajay K. Nooka, MD, MPH

Why It Matters

High infection rates have threatened the uptake of BCMA bispecifics; clear mitigation strategies enable clinicians to safely deliver a high‑efficacy option for a hard‑to‑treat myeloma population, expanding therapeutic choice and market potential.

Key Takeaways

• Grade 3‑4 infections affect 50‑60% of BCMA bispecific patients
• Monthly IVIG reduces infection‑related deaths to near zero
• Withhold dosing for fever or active infection, start antibiotics early
• Use growth factors to prevent neutropenia during therapy
• Vaccinate before treatment; continue if possible during therapy

Pulse Analysis

BCMA bispecific antibodies, such as teclistamab, have emerged as a breakthrough for patients with relapsed or refractory multiple myeloma, offering deep and durable responses. The FDA’s full approval marks a pivotal moment, yet early trial data revealed alarming grade 3‑4 infection rates, largely driven by B‑cell depletion and the heightened vulnerability during the COVID‑19 pandemic. Understanding these risks is essential for oncologists who must balance efficacy with patient safety, especially as the market anticipates broader adoption of bispecific platforms.

In response, Dr. Ajay K. Nooka outlined a pragmatic mitigation framework that is already proving effective in the MajesTEC‑3 trial. Monthly intravenous immunoglobulin (IVIG) supplementation has driven infection‑related mortality to near zero, while routine use of granulocyte‑colony stimulating factors curtails neutropenia, a key precursor to bacterial sepsis. Clinicians are urged to pause dosing at the first sign of fever or active infection and to initiate empiric antibiotics promptly, treating any febrile episode as a potential gram‑negative threat. Vaccination strategies—administered before therapy when feasible and continued during treatment—further bolster immune defenses despite underlying hypogammaglobulinemia.

The implications extend beyond individual patient outcomes. By establishing clear “guardrails,” the oncology community can confidently integrate BCMA bispecifics into standard care pathways, unlocking revenue streams for manufacturers and encouraging continued investment in next‑generation immunotherapies. Moreover, the demonstrated success of prophylactic IVIG and growth‑factor protocols may set a precedent for managing infection risks across other cellular and antibody‑based treatments, shaping future clinical guidelines and regulatory expectations.